Clinical trial
Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
NCT01696617 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 10, 2012
- Completion date
- February 28, 2019
- Enrollment
- 46 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.